Hutchmed’s divestiture; Xgene reports Phase 2b win for non-opioid pain drug
Plus, news about Hookipa and Capricor Therapeutics:
Hutchmed divests 45% stake in Chinese company: Hutchmed will get about $608 million in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
